24 completed, 3 withdrawn, 2 terminated, 1 active not recruiting. 16 Phase 2, 14 Phase 3, 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Completed 11, Terminated 2, Withdrawn 2, Unknown 1 |
| Phase 3 | 14 | Completed 10, Active not recruiting 1, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 1 | 7 | Completed 5, Withdrawn 2 |
Follow vinflunine: new trials by email Literature Review of vinflunine trials Research Report on vinflunine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) Sacituzumab tirumotecan, Vinflunine, Docetaxel - Bladder Cancer | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 590 | 2026-04-23 | 2026-11-10 |
| Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread Sacituzumab Govitecan-hziy, Paclitaxel, Docetaxel - Locally Advanced or Metastatic Unresectable Urothelial Cancer | Phase 3 | Completed | Gilead Sciences | 711 | 2021-01-13 | 2026-06-02 |
| A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) Enfortumab Vedotin, Docetaxel, Vinflunine - Ureteral Cancer, Urothelial Cancer | Phase 3 | Completed | Astellas Pharma Global Development, Inc. | 608 | 2018-06-27 | 2026-01-09 |
| A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations Erdafitinib, Vinflunine, Docetaxel - Urothelial Cancer | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 629 | 2018-03-23 | 2026-11-03 |
| Phase Ib/II Study Assessing the Neo-adjuvant Combination Therapy of Vinflunine With Cisplatin Followed by Radical Cystectomy in Patients With Muscle-invasive Bladder Cancer (JaNEO) Vinflunine, Cisplatin, Radical cystectomy - Bladder Cancer | Phase 1 / Phase 2 | Withdrawn | Ligartis GmbH | 2016-07-01 | 2018-02-13 | |
| A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211] Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody, Docetaxel, Paclitaxel - Bladder Cancer | Phase 3 | Completed | Hoffmann-La Roche | 931 | 2015-01-13 | 2019-08-01 |
| A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045) pembrolizumab, paclitaxel, vinflunine - Urothelial Cancer | Phase 3 | Completed | Merck Sharp & Dohme LLC | 542 | 2014-10-22 | 2021-09-20 |
| Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer Vinflunine, Methotrexate - Recurrent or Metastatic Head and Neck Carcinoma | Phase 3 | Completed | Pierre Fabre Medicament | 459 | 2014-04-25 | 2019-03-05 |
| A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function Vinflunine, Gemcitabine, Carboplatin - Urothelial Carcinoma, Bladder Cancer | Phase 2 | Completed | Dr Anders Ullén | 62 | 2014-04-01 | 2019-10-08 |
| A Phase II Trial of Vinflunine Chemotherapy in Locally-advanced and Metastatic Carcinoma of the Penis (VinCaP) Vinflunine - Locally-advanced or Metastatic Penile Neoplasms | Phase 2 | Completed | Institute of Cancer Research, United Kingdom | 22 | 2014-03-17 | 2020-07-23 |
| Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer vinflunine, Capecitabine - Malignant Neoplasm of Breast | Phase 3 | Completed | Pierre Fabre Medicament | 112 | 2013-09-01 | 2019-05-02 |
| Cabazitaxel vs. Vinflunine in Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium (TCCU) Cabazitaxel, Vinflunine - Urothelium Transitional Cell Carcinoma | Phase 2 / Phase 3 | Unknown | Associació per a la Recerca Oncologica, Spain | 372 | 2012-10-01 | 2014-01-28 |
| Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract Vinflunine, Sorafenib - Urothelial Carcinoma, Bladder Cancer | Phase 1 | Completed | Dr Anders Ullén | 22 | 2012-05-01 | 2019-04-26 |
| Clinical Trial With Vinflunine as Maintenance Therapy in Metastatic Urothelial Cancer Vinflunine, Undefined (standard care) - Carcinoma, Transitional Cell | Phase 2 | Completed | Spanish Oncology Genito-Urinary Group | 86 | 2012-02-01 | 2019-04-04 |
| Pazopanib and Vinflunine in Urothelial Cancer of the Bladder Pazopanib as add-on to vinflunine - Advanced Urothelial Cancer of Bladder After Failure of Platinum-containing Therapy. | Phase 1 / Phase 2 | Completed | Prof. Dr. Thomas Otto | 5 | 2011-03-01 | 2012-10-10 |
| JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin Vinflunine, Gemcitabine, Vinflunine, Carboplatin - Bladder Transitional Cell Carcinoma Stage IV | Phase 2 | Completed | Pierre Fabre Medicament | 69 | 2011-02-01 | 2015-12-08 |
| Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer vinflunine, Alkylating agent of physician choice registered in cancer - Breast Cancer, Metastases | Phase 3 | Completed | Pierre Fabre Medicament | 594 | 2009-07-01 | 2019-09-16 |
| Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer Vinflunine plus Capecitabine, Capecitabine - Breast Cancer | Phase 3 | Completed | Pierre Fabre Medicament | 770 | 2009-05-01 | 2022-04-28 |
| A Study of the Interaction of Rifampin and Vinflunine in Subjects With Advanced Cancer Vinflunine, Rifampin - Cancer | Phase 1 | Withdrawn | Bristol-Myers Squibb | 2007-09-01 | 2015-09-01 | |
| Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC cetuximab, vinflunine - Lung Cancer | Phase 2 | Terminated | UNC Lineberger Comprehensive Cancer Center | 18 | 2007-08-01 | 2017-06-09 |
Showing 20 of 32. Sign in to see all of them.
Urinary Bladder Neoplasms (12) · Carcinoma, Transitional Cell (7) · Breast Neoplasms (5) · Neoplasm Metastasis (5) · Neoplasms (4) · Ureteral Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (2) · Lung Neoplasms (2) · Recurrence (2) · Urethral Neoplasms (2) · Breast Neoplasms, Male (1) · Carcinoma (1) · Carcinoma, Small Cell (1) · Kidney Neoplasms (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1)
Bristol-Myers Squibb (6) · Pierre Fabre Medicament (6) · SCRI Development Innovations, LLC (3) · Dr Anders Ullén (2) · Merck Sharp & Dohme LLC (2) · UNC Lineberger Comprehensive Cancer Center (2) · Alliance for Clinical Trials in Oncology (1) · Associació per a la Recerca Oncologica, Spain (1) · Astellas Pharma Global Development, Inc. (1) · Gilead Sciences (1) · Hoffmann-La Roche (1) · Institute of Cancer Research, United Kingdom (1) · Janssen Research & Development, LLC (1) · Ligartis GmbH (1) · Prof. Dr. Thomas Otto (1)
United States (16) · France (11) · Spain (11) · Italy (9) · United Kingdom (9) · Belgium (8) · Canada (8) · Germany (8) · Australia (7) · South Korea (7) · Taiwan (7) · Austria (6) · Greece (6) · Russia (6) · Sweden (6)
Albert Font, MD (1) · Alvaro Moreno, MD (1) · Binghe XU, MD (1) · David R. Spigel, MD (1) · Denise A Yardley, MD (1) · Elizabeth C. Dees, MD (1) · Joaquim Bellmunt, MD (1)
PMID 29562804, PMID 26454620, PMID 20158340, PMID 20521355, PMID 20690806, PMID 26673352, PMID 27939400, PMID 28212060, PMID 28389316, PMID 28419193, PMID 29268948, PMID 29447329, PMID 29481630, PMID 29590008, PMID 30552156, PMID 31050707, PMID 31395089, PMID 31542806, PMID 31648851, PMID 33241650, PMID 33577729, PMID 33902955, PMID 34671131, PMID 35101941, PMID 35247908, PMID 36494006, PMID 37870920, PMID 38418343, PMID 39472646, PMID 40037029, PMID 41277126
2014 (2), 2017 (2), 2008 (1), 2016 (1), 2023 (1)